Adcetris is indicated for treatment of patients with classical Hodgkin Lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

Subtype:

Hodgkin Lymphoma (HL)

License:

FDA

Class:

CD30 ADC

R/R

PIhttp://www.seattlegenetics.com/pdf/adcetris_USPI.pdf 

1. Approved Labelling

Adcetris is indicated for treatment of patients with classical Hodgkin Lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

2. Treatment Regimen 

Administer Adcetris as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity. The recommended dose is 1.8 mg/kg. Reduce dose in patients with mild hepatic impairment. 

3. AE/Warnings

Please see section 5 of the PI.

 

 

 

 

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.